The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema

Trial Profile

The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Eczema
  • Focus Therapeutic Use
  • Acronyms ADAPT
  • Most Recent Events

    • 02 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 01 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ISRCTN: Current Controlled Trials.
    • 02 Dec 2015 Accrual to date is 59% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top